Aquestive Therapeutics Shares Rise 12% on Anaphylm Trial Timeline
By Denny Jacob
Aquestive Therapeutics shares rose 12% to $1.72 on news it expects to continue starting its clinical trial of oral epinephrine product candidate anaphylm in the fourth quarter.
The stock is up 91% on the year so far through Wednesday's trading session.
The pharmaceutical company said it intends to commence the trial in the fourth quarter following alignment with the Food and Drug Administration. It noted its current development plan continues to include a standard repeat-dose study of anaphylm and an already-approved comparator.
Chief Executive Daniel Barber said Aquestive is focused on the work necessary to reach its goal of filing its new drug application in 2024. He added that anaphylm has demonstrated clinical results comparable to other known autoinjectors such as the EpiPen and Auvi-Q for the emergency treatment of severe allergic reactions including anaphylaxis.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
September 20, 2023 10:42 ET (14:42 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track